X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (2296) 2296
humans (1944) 1944
male (1478) 1478
anilides - therapeutic use (1447) 1447
anilides - pharmacology (802) 802
animals (783) 783
middle aged (664) 664
aged (634) 634
female (572) 572
prostatic neoplasms - drug therapy (527) 527
antineoplastic agents - therapeutic use (420) 420
anilides - adverse effects (400) 400
oncology (400) 400
pyridines - therapeutic use (396) 396
anilides - administration & dosage (395) 395
androgen antagonists - therapeutic use (386) 386
mice (358) 358
pharmacology & pharmacy (355) 355
abridged index medicus (342) 342
prostate cancer (341) 341
adult (334) 334
cancer (331) 331
tosyl compounds (305) 305
nitriles (303) 303
treatment outcome (275) 275
urology & nephrology (250) 250
aged, 80 and over (247) 247
rats (242) 242
prostatic neoplasms - pathology (239) 239
care and treatment (228) 228
cell line, tumor (227) 227
encainide (218) 218
nitriles - therapeutic use (206) 206
tosyl compounds - therapeutic use (197) 197
bicalutamide (174) 174
dose-response relationship, drug (171) 171
time factors (171) 171
pyridines - pharmacology (169) 169
anti-arrhythmia agents - therapeutic use (166) 166
drug therapy, combination (166) 166
carcinoma (165) 165
signal transduction - drug effects (164) 164
carcinoma, basal cell - drug therapy (162) 162
expression (160) 160
skin neoplasms - drug therapy (159) 159
antineoplastic agents, hormonal - therapeutic use (157) 157
flutamide - therapeutic use (155) 155
analysis (154) 154
antineoplastic agents - pharmacology (151) 151
therapy (151) 151
research (143) 143
clinical trials as topic (141) 141
prostate-specific antigen - blood (139) 139
article (138) 138
health aspects (133) 133
anilides - chemistry (132) 132
antineoplastic combined chemotherapy protocols - therapeutic use (132) 132
metastasis (131) 131
arrhythmias, cardiac - drug therapy (128) 128
ppar gamma - metabolism (120) 120
antineoplastic agents - adverse effects (119) 119
pyridines - adverse effects (119) 119
hedgehog proteins - antagonists & inhibitors (117) 117
prostatic neoplasms - blood (117) 117
ppar gamma - antagonists & inhibitors (116) 116
drug therapy (115) 115
disease models, animal (113) 113
anilides - pharmacokinetics (112) 112
antiviral agents - therapeutic use (111) 111
vismodegib (111) 111
cell proliferation - drug effects (110) 110
follow-up studies (106) 106
orchiectomy (105) 105
tumors (104) 104
carbamates - therapeutic use (103) 103
uracil - analogs & derivatives (103) 103
hepatitis c, chronic - drug therapy (102) 102
prostatic neoplasms - metabolism (101) 101
activation (100) 100
administration, oral (100) 100
disease progression (100) 100
adenocarcinoma - drug therapy (99) 99
combined modality therapy (99) 99
dermatology (99) 99
chemotherapy (98) 98
macrocyclic compounds - therapeutic use (98) 98
skin neoplasms - pathology (97) 97
apoptosis (96) 96
medicine & public health (96) 96
biochemistry & molecular biology (94) 94
flutamide (94) 94
neoplasm staging (93) 93
patients (93) 93
prostatic neoplasms - surgery (93) 93
apoptosis - drug effects (92) 92
hepacivirus - genetics (92) 92
electrocardiography (91) 91
androgen antagonists - administration & dosage (90) 90
receptors, androgen - metabolism (90) 90
androgen antagonists - adverse effects (89) 89
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2308) 2308
German (49) 49
Japanese (24) 24
French (20) 20
Italian (14) 14
Spanish (10) 10
Chinese (9) 9
Russian (9) 9
Czech (7) 7
Polish (6) 6
Norwegian (4) 4
Dutch (3) 3
Portuguese (2) 2
Finnish (1) 1
Hebrew (1) 1
Hungarian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
Journal Article
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin | Index Medicus | Abridged Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 25, pp. 2375 - 2382
In this study, 34 liver-transplant recipients with recurrent HCV genotype 1 infection were treated with the interferon-free regimen of ombitasvir–ABT-450/r,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | MULTICENTER | VIRUS-INFECTION | TELAPREVIR | THERAPY | DASABUVIR | HEPATITIS-C RECURRENCE | GRAFT | RIBAVIRIN | PEGINTERFERON-ALPHA-2B | Anilides - therapeutic use | Liver Transplantation | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Calcineurin Inhibitors - blood | Young Adult | Ribavirin - administration & dosage | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Antiviral Agents - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Calcineurin Inhibitors - therapeutic use | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Uracil - analogs & derivatives | Care and treatment | Usage | Ritonavir | Liver | Dosage and administration | Transplantation | Hepatitis C | Ribavirin | Headache | Transplants & implants | Erythropoietin | Syngeneic grafts | Calcineurin | Calcineurin inhibitors | Blood transfusion | Immunosuppressive agents | Hepatitis | Allografts | Drug therapy | Genotypes | Antiviral agents | Recurrent infection | Fatigue | Proteinase inhibitors | Patients | RNA-directed RNA polymerase | Cough | Blood levels | Graft rejection | Fibrosis | Interferon | Antiviral drugs | Liver transplantation | Index Medicus | Abridged Index Medicus | Medicaments antivírics | Hepatitis C virus | Virus de l'hepatitis C | Trasplantament hepàtic | Hepatic transplantation
Journal Article
Breast Cancer Research, ISSN 1465-5411, 01/2014, Volume 16, Issue 1, pp. R7 - R7
Journal Article
Cancer Research, ISSN 0008-5472, 03/2012, Volume 72, Issue 6, pp. 1494 - 1503
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1973 - 1982
In patients with HCV genotype 1 infection and cirrhosis, the rate of sustained virologic response was 92% with three new antiviral agents plus ribavirin for 12... 
SUSTAINED VIROLOGICAL RESPONSE | ALL-CAUSE MORTALITY | UNITED-STATES | MEDICINE, GENERAL & INTERNAL | VIRUS-INFECTION | TELAPREVIR | THERAPY | GENOTYPE 1 INFECTION | BOCEPREVIR | HCV INFECTION | EPIDEMIOLOGY | Recurrence | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Hepatitis C, Chronic - complications | Adult | Female | Drug Therapy, Combination | Hepacivirus - isolation & purification | Liver Cirrhosis - drug therapy | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Genotype | Logistic Models | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Complications and side effects | Evaluation | Care and treatment | Usage | Hepatitis C | Liver cirrhosis | Ribavirin | Headache | Antiviral agents | Ritonavir | Body weight | Fatigue | Infections | Nausea | Proteinase inhibitors | RNA polymerase | Patients | Cirrhosis | Liver cancer | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes | Index Medicus | Abridged Index Medicus | Cirrosi hepàtica | Inhibidors enzimàtics | Enzyme inhibitors | Hepatic cirrhosis
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 21, pp. 1983 - 1992
Journal Article
Cancer Cell, ISSN 1535-6108, 01/2013, Volume 23, Issue 1, pp. 23 - 34
Journal Article